201 related articles for article (PubMed ID: 28835699)
1. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
Tan YC; Mirzapoiazova T; Won BM; Zhu L; Srivastava MK; Vokes EE; Husain AN; Batra SK; Sharma S; Salgia R
Sci Rep; 2017 Aug; 7(1):9192. PubMed ID: 28835699
[TBL] [Abstract][Full Text] [Related]
2. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
Wu W; Bi C; Credille KM; Manro JR; Peek VL; Donoho GP; Yan L; Wijsman JA; Yan SB; Walgren RA
Clin Cancer Res; 2013 Oct; 19(20):5699-710. PubMed ID: 23989980
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma.
Hong SY; Kao YR; Lee TC; Wu CW
Cancer Res; 2018 Sep; 78(17):4984-4996. PubMed ID: 29945960
[TBL] [Abstract][Full Text] [Related]
5. Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy.
Zhang S; Sun Y
EBioMedicine; 2020 Apr; 54():102718. PubMed ID: 32268269
[No Abstract] [Full Text] [Related]
6. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
7. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
[TBL] [Abstract][Full Text] [Related]
8. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
9. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
10. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
11. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Kawada I; Hasina R; Arif Q; Mueller J; Smithberger E; Husain AN; Vokes EE; Salgia R
Cancer Res; 2014 Feb; 74(3):884-95. PubMed ID: 24305878
[TBL] [Abstract][Full Text] [Related]
12. Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma.
Li P; Liu H; Zhang Z; Lv X; Wang H; Ma J; Ma Z; Qu X; Teng YE
Med Sci Monit; 2018 Jan; 24():623-635. PubMed ID: 29384143
[TBL] [Abstract][Full Text] [Related]
13. Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by
Iommelli F; De Rosa V; Terlizzi C; Monti M; Panico M; Fonti R; Del Vecchio S
Clin Cancer Res; 2018 Jul; 24(13):3126-3136. PubMed ID: 29618618
[No Abstract] [Full Text] [Related]
14. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
15. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
[No Abstract] [Full Text] [Related]
16. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
[TBL] [Abstract][Full Text] [Related]
17. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Wang S; Xu L; Che X; Li C; Xu L; Hou K; Fan Y; Wen T; Qu X; Liu Y
FEBS Lett; 2018 Feb; 592(4):621-630. PubMed ID: 29364514
[TBL] [Abstract][Full Text] [Related]
18. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y
Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056
[TBL] [Abstract][Full Text] [Related]
20. LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.
Zhu T; An S; Choy MT; Zhou J; Wu S; Liu S; Liu B; Yao Z; Zhu X; Wu J; He Z
J Cell Mol Med; 2019 Mar; 23(3):1852-1864. PubMed ID: 30515972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
